Draft FDA Reorganization Would Unite All Product Centers

Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.

Puzzle pieces being brought together. Concept: Merger, unity.
(Summit Art Creations/Shutterstock)
Key Takeaways
  • CDER and CBER would cease being independent centers under a planned HHS reorganization of the FDA that would merge all of FDA's product review groups.

All of the US Food and Drug Administration’s product review and regulatory decision-making across drugs, biologics, devices, tobacco and foods...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medtech Insight

More from Regulation